Sugammadex for Reversal of Neuromuscular Blockade: Uses and Limitations

被引:33
作者
Hawkins, Jesse [1 ]
Khanna, Sandeep [1 ]
Argalious, Maged [1 ]
机构
[1] Cleveland Clin, Cleveland, OH 44106 USA
关键词
Sugammadex; neuromuscular blocker; aminosteroids; non-depolarizing muscle relaxants; neuromuscular reversal; neuromuscular monitoring; MORBIDLY OBESE; ROCURONIUM BROMIDE; MUSCLE-RELAXATION; BODY-WEIGHT; MG KG(-1); NEOSTIGMINE; HYPERSENSITIVITY; VECURONIUM; SAFETY; AGENT;
D O I
10.2174/1381612825666190704101145
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sugammadex is a reversal agent that was engineered to reverse the effects of aminosteroid muscle relaxants. It is a modified gamma-cyclodextrin, i.e. a large glucose molecule bound in a ring-like structure. Sugammadex, when injected intravenously, creates a concentration gradient favoring the movement of aminosteroid muscle relaxants from the neuromuscular junction back into the plasma, and then encapsulates the aminosteroid muscle relaxants within its inner structure by forming tight water-soluble complexes. The dissociation of the aminosteroidal muscle relaxant from the post-synaptic acetylcholine receptors is responsible for the termination of neuromuscular blockade. This review article presents the current indication, mechanism of action, limitations, side effects and contraindications of sugammadex. An overview of monitoring of the adequacy of reversal of aminosteroid muscle relaxants with sugammadex is presented. Moreover, the use of sugammadex in special situations, including "cannot intubate cannot oxygenate" scenarios is also described.
引用
收藏
页码:2140 / 2148
页数:9
相关论文
共 73 条
[1]   Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade [J].
Abrishami, Amir ;
Ho, Joyce ;
Wong, Jean ;
Yin, Ling ;
Chung, Frances .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (04)
[2]   Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: Synthesis and structure-activity relationships [J].
Adam, JM ;
Bennett, DJ ;
Bom, A ;
Clark, JK ;
Feilden, H ;
Hutchinson, EJ ;
Palin, R ;
Prosser, A ;
Rees, DC ;
Rosair, GM ;
Stevenson, D ;
Tarver, GJ ;
Zhang, MQ .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (09) :1806-1816
[3]  
[Anonymous], 2017, BRID SUG PRESCR INF
[4]   The use of succinylcholine after sugammadex reversal [J].
Asakura, Chie ;
Iwasaki, Hajime .
JOURNAL OF ANESTHESIA, 2016, 30 (05) :915-915
[5]   Residual neuromuscular block is a risk factor for postoperative pulmonary complications - A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium [J].
Berg, H ;
VibyMogensen, J ;
Roed, J ;
Mortensen, CR ;
Engbaek, J ;
Skovgaard, LT ;
Krintel, JJ .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1997, 41 (09) :1095-1103
[6]   Severe bradycardia and asystole after sugammadex [J].
Bhavani, S. S. .
BRITISH JOURNAL OF ANAESTHESIA, 2018, 121 (01) :95-96
[7]  
Bom A, 2002, ANGEW CHEM INT EDIT, V41, P266
[8]   Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study [J].
Brueckmann, B. ;
Sasaki, N. ;
Grobara, P. ;
Li, M. K. ;
Woo, T. ;
de Bie, J. ;
Maktabi, M. ;
Lee, J. ;
Kwo, J. ;
Pino, R. ;
Sabouri, A. S. ;
McGovern, F. ;
Staehr-Rye, A. K. ;
Eikermann, M. .
BRITISH JOURNAL OF ANAESTHESIA, 2015, 115 (05) :743-751
[9]   Current Status of Neuromuscular Reversal and Monitoring Challenges and Opportunities [J].
Brull, Sorin J. ;
Kopman, Aaron F. .
ANESTHESIOLOGY, 2017, 126 (01) :173-190
[10]   Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment [J].
Cammu, G. ;
Van Vlem, B. ;
van den Heuvel, M. ;
Stet, L. ;
el Galta, R. ;
Eloot, S. ;
Demeyer, I. .
BRITISH JOURNAL OF ANAESTHESIA, 2012, 109 (03) :382-390